Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Alx Oncology Holdings (ALXO) EBIAT (2019 - 2026)

Alx Oncology Holdings' EBIAT history spans 5 years, with the latest figure at -$45.5 million for Q4 2023.

  • On a quarterly basis, EBIAT fell 48.07% to -$45.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$160.8 million, a 30.23% decrease, with the full-year FY2025 number at -$101.7 million, up 24.59% from a year prior.
  • EBIAT hit -$45.5 million in Q4 2023 for Alx Oncology Holdings, up from -$51.0 million in the prior quarter.
  • Over the last five years, EBIAT for ALXO hit a ceiling of -$3.0 million in Q3 2019 and a floor of -$51.0 million in Q3 2023.
  • Historically, EBIAT has averaged -$22.6 million across 5 years, with a median of -$24.5 million in 2022.
  • Biggest five-year swings in EBIAT: tumbled 234.46% in 2020 and later fell 3.76% in 2023.
  • Tracing ALXO's EBIAT over 5 years: stood at -$7.8 million in 2019, then plummeted by 141.81% to -$18.8 million in 2020, then tumbled by 51.48% to -$28.4 million in 2021, then fell by 7.99% to -$30.7 million in 2022, then tumbled by 48.07% to -$45.5 million in 2023.
  • Business Quant data shows EBIAT for ALXO at -$45.5 million in Q4 2023, -$51.0 million in Q3 2023, and -$34.2 million in Q2 2023.